| Year |
Citation |
Score |
| 2024 |
Picco G, Rao Y, Al Saedi A, Lee Y, Vieira SF, Bhosle S, May K, Herranz-Ors C, Walker SJ, Shenje R, Dincer C, Gibson F, Banerjee R, Hewitson Z, Werner T, ... ... Garnett MJ, et al. Novel WRN Helicase Inhibitors Selectively Target Microsatellite Unstable Cancer Cells. Cancer Discovery. PMID 38587317 DOI: 10.1158/2159-8290.CD-24-0052 |
0.412 |
|
| 2024 |
Bashi AC, Coker EA, Bulusu KC, Jaaks P, Crafter C, Lightfoot H, Milo M, McCarten K, Jenkins DF, van der Meer D, Lynch JT, Barthorpe S, Andersen CL, Barry ST, Beck A, ... ... Garnett MJ, et al. Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations. Cancer Discovery. OF1-OF20. PMID 38456804 DOI: 10.1158/2159-8290.CD-23-0388 |
0.715 |
|
| 2024 |
Pacini C, Duncan E, Gonçalves E, Gilbert J, Bhosle S, Horswell S, Karakoc E, Lightfoot H, Curry E, Muyas F, Bouaboula M, Pedamallu CS, Cortes-Ciriano I, Behan FM, Zalmas LP, ... ... Garnett MJ, et al. A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization. Cancer Cell. PMID 38215750 DOI: 10.1016/j.ccell.2023.12.016 |
0.408 |
|
| 2023 |
Trastulla L, Savino A, Beltrao P, Ciriano IC, Fenici P, Garnett MJ, Guerini I, Bigas NL, Mattaj I, Petsalaki E, Riva L, Tape CJ, Leeuwen JV, Sharma S, Vazquez F, et al. Highlights from the 1st European cancer dependency map symposium and workshop. Febs Letters. 597: 1921-1927. PMID 37487655 DOI: 10.1002/1873-3468.14699 |
0.361 |
|
| 2023 |
Nair NU, Greninger P, Zhang X, Friedman AA, Amzallag A, Cortez E, Sahu AD, Lee JS, Dastur A, Egan RK, Murchie E, Ceribelli M, Crowther GS, Beck E, McClanaghan J, ... ... Garnett MJ, et al. A landscape of response to drug combinations in non-small cell lung cancer. Nature Communications. 14: 3830. PMID 37380628 DOI: 10.1038/s41467-023-39528-9 |
0.443 |
|
| 2023 |
Dorard C, Madry C, Buhard O, Toifl S, Didusch S, Ratovomanana T, Letourneur Q, Dolznig H, Garnett MJ, Duval A, Baccarini M. RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status. Oncogene. PMID 37020037 DOI: 10.1038/s41388-023-02683-w |
0.345 |
|
| 2022 |
Dunn S, Eberlein C, Yu J, Gris-Oliver A, Ong SH, Yelland U, Cureton N, Staniszewska A, McEwen R, Fox M, Pilling J, Hopcroft P, Coker EA, Jaaks P, Garnett MJ, et al. AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors. Oncogene. PMID 36241868 DOI: 10.1038/s41388-022-02482-9 |
0.708 |
|
| 2022 |
Gonçalves E, Poulos RC, Cai Z, Barthorpe S, Manda SS, Lucas N, Beck A, Bucio-Noble D, Dausmann M, Hall C, Hecker M, Koh J, Lightfoot H, Mahboob S, Mali I, ... ... Garnett MJ, et al. Pan-cancer proteomic map of 949 human cell lines. Cancer Cell. PMID 35839778 DOI: 10.1016/j.ccell.2022.06.010 |
0.37 |
|
| 2022 |
Schipper LJ, Zeverijn LJ, Garnett MJ, Voest EE. Can Drug Repurposing Accelerate Precision Oncology? Cancer Discovery. OF1-OF8. PMID 35642948 DOI: 10.1158/2159-8290.CD-21-0612 |
0.447 |
|
| 2022 |
Jaaks P, Coker EA, Vis DJ, Edwards O, Carpenter EF, Leto SM, Dwane L, Sassi F, Lightfoot H, Barthorpe S, van der Meer D, Yang W, Beck A, Mironenko T, Hall C, ... ... Garnett MJ, et al. Effective drug combinations in breast, colon and pancreatic cancer cells. Nature. PMID 35197630 DOI: 10.1038/s41586-022-04437-2 |
0.726 |
|
| 2021 |
Nguyen PBH, Ohnmacht AJ, Sharifli S, Garnett MJ, Menden MP. Inferred Ancestral Origin of Cancer Cell Lines Associates with Differential Drug Response. International Journal of Molecular Sciences. 22. PMID 34576298 DOI: 10.3390/ijms221810135 |
0.494 |
|
| 2021 |
Picco G, Cattaneo CM, van Vliet EJ, Crisafulli G, Rospo G, Consonni S, Vieira SF, Sanchez Rodriguez I, Cancelliere C, Banerjee R, Schipper LJ, Oddo D, Dijkstra KK, Cinatl J, Michaelis M, ... ... Garnett MJ, et al. Werner helicase is a synthetic-lethal vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy and Immunotherapy. Cancer Discovery. PMID 33837064 DOI: 10.1158/2159-8290.CD-20-1508 |
0.381 |
|
| 2021 |
Pacini C, Dempster JM, Boyle I, Gonçalves E, Najgebauer H, Karakoc E, van der Meer D, Barthorpe A, Lightfoot H, Jaaks P, McFarland JM, Garnett MJ, Tsherniak A, Iorio F. Integrated cross-study datasets of genetic dependencies in cancer. Nature Communications. 12: 1661. PMID 33712601 DOI: 10.1038/s41467-021-21898-7 |
0.349 |
|
| 2020 |
Francies HE, McDermott U, Garnett MJ. Genomics-guided pre-clinical development of cancer therapies. Nature Cancer. 1: 482-492. PMID 35121986 DOI: 10.1038/s43018-020-0067-x |
0.444 |
|
| 2020 |
Eduati F, Jaaks P, Wappler J, Cramer T, Merten CA, Garnett MJ, Saez-Rodriguez J. Patient-specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies. Molecular Systems Biology. 16: e9690. PMID 33438807 DOI: 10.15252/msb.209690 |
0.323 |
|
| 2020 |
Winkler C, Armenia J, Jones GN, Tobalina L, Sale MJ, Petreus T, Baird T, Serra V, Wang AT, Lau A, Garnett MJ, Jaaks P, Coker EA, Pierce AJ, O'Connor MJ, et al. SLFN11 informs on standard of care and novel treatments in a wide range of cancer models. British Journal of Cancer. PMID 33339894 DOI: 10.1038/s41416-020-01199-4 |
0.675 |
|
| 2020 |
Wang D, Hensman J, Kutkaite G, Toh TS, Galhoz ACP, Dry JR, Saez-Rodriguez J, Garnett MJ, Menden MP, Dondelinger F. A statistical framework for assessing pharmacological response and biomarkers using uncertainty estimates. Elife. 9. PMID 33274713 DOI: 10.7554/eLife.60352 |
0.373 |
|
| 2020 |
Flemington V, Davies EJ, Robinson D, Sandin LC, Delpuech O, Zhang P, Hanson L, Farrington P, Bell S, Falenta K, Gibbons FD, Lindsay N, Smith A, Wilson J, Roberts K, ... ... Garnett MJ, et al. AZD0364 is a potent and selective ERK1/2 inhibitor which enhances anti-tumour activity in KRAS mutant tumour models when combined with the MEK inhibitor selumetinib. Molecular Cancer Therapeutics. PMID 33273059 DOI: 10.1158/1535-7163.MCT-20-0002 |
0.681 |
|
| 2020 |
Dwane L, Behan FM, Gonçalves E, Lightfoot H, Yang W, van der Meer D, Shepherd R, Pignatelli M, Iorio F, Garnett MJ. Project Score database: a resource for investigating cancer cell dependencies and prioritizing therapeutic targets. Nucleic Acids Research. PMID 33068406 DOI: 10.1093/nar/gkaa882 |
0.394 |
|
| 2020 |
Chai AWY, Yee PS, Price S, Yee SM, Lee HM, Tiong VK, Gonçalves E, Behan FM, Bateson J, Gilbert J, Tan AC, McDermott U, Garnett MJ, Cheong SC. Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway. Elife. 9. PMID 32990596 DOI: 10.7554/eLife.57761 |
0.3 |
|
| 2020 |
Balachander SB, Criscione SW, Byth KF, Cidado J, Adam A, MacIntyre T, Wen S, Lawson D, Burke K, Lubinski TJ, Tyner JW, Kurtz SE, McWeeney SK, Varnes J, Diebold RB, ... ... Garnett MJ, et al. AZD4320, a dual inhibitor of Bcl-2 and Bcl-xL, induces tumor regression in hematological cancer models without dose-limiting thrombocytopenia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32988967 DOI: 10.1158/1078-0432.CCR-20-0863 |
0.688 |
|
| 2020 |
Gonçalves E, Segura-Cabrera A, Pacini C, Picco G, Behan FM, Jaaks P, Coker EA, van der Meer D, Barthorpe A, Lightfoot H, Mironenko T, Beck A, Richardson L, Yang W, Lleshi E, ... ... Garnett MJ, et al. Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens. Molecular Systems Biology. 16: e9405. PMID 32627965 DOI: 10.15252/msb.20199405 |
0.689 |
|
| 2020 |
Yang M, Jaaks P, Dry J, Garnett M, Menden MP, Saez-Rodriguez J. Stratification and prediction of drug synergy based on target functional similarity. Npj Systems Biology and Applications. 6: 16. PMID 32487991 DOI: 10.1038/s41540-020-0136-x |
0.456 |
|
| 2020 |
Najgebauer H, Yang M, Francies HE, Pacini C, Stronach EA, Garnett MJ, Saez-Rodriguez J, Iorio F. CELLector: Genomics-Guided Selection of Cancer In Vitro Models. Cell Systems. 10: 424-432.e6. PMID 32437684 DOI: 10.1016/J.Cels.2020.04.007 |
0.343 |
|
| 2020 |
Eduati F, Jaaks P, Wappler J, Cramer T, Merten CA, Garnett MJ, Saez-Rodriguez J. Patient-specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies. Molecular Systems Biology. 16: e8664. PMID 32073727 DOI: 10.15252/msb.20188664 |
0.362 |
|
| 2020 |
Francies HE, Barthorpe A, McLaren-Douglas A, Barendt WJ, Garnett MJ. Drug Sensitivity Assays of Human Cancer Organoid Cultures. Methods in Molecular Biology (Clifton, N.J.). 1576: 339-351. PMID 27628132 DOI: 10.1007/7651_2016_10 |
0.431 |
|
| 2019 |
Dempster JM, Pacini C, Pantel S, Behan FM, Green T, Krill-Burger J, Beaver CM, Younger ST, Zhivich V, Najgebauer H, Allen F, Gonçalves E, Shepherd R, Doench JG, Yusa K, ... ... Garnett MJ, et al. Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets. Nature Communications. 10: 5817. PMID 31862961 DOI: 10.1038/S41467-019-13805-Y |
0.324 |
|
| 2019 |
Driehuis E, van Hoeck A, Moore K, Kolders S, Francies HE, Gulersonmez MC, Stigter ECA, Burgering B, Geurts V, Gracanin A, Bounova G, Morsink FH, Vries R, Boj S, van Es J, ... ... Garnett MJ, et al. Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Proceedings of the National Academy of Sciences of the United States of America. PMID 31818951 DOI: 10.1073/Pnas.1911273116 |
0.374 |
|
| 2019 |
Guo T, Luna A, Rajapakse VN, Koh CC, Wu Z, Liu W, Sun Y, Gao H, Menden MP, Xu C, Calzone L, Martignetti L, Auwerx C, Buljan M, Banaei-Esfahani A, ... ... Garnett MJ, et al. Quantitative Proteome Landscape of the NCI-60 Cancer Cell Lines. Iscience. 21: 664-680. PMID 31733513 DOI: 10.1016/J.Isci.2019.10.059 |
0.334 |
|
| 2019 |
Lazzari L, Corti G, Picco G, Isella C, Montone M, Arcella P, Durinikova E, Zanella ER, Novara L, Barbosa F, Cassingena A, Cancelliere C, Medico E, Sartore-Bianchi A, Siena S, ... Garnett MJ, et al. Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 25: 6243-6259. PMID 31375513 DOI: 10.1158/1078-0432.Ccr-18-3440 |
0.31 |
|
| 2019 |
Menden MP, Wang D, Mason MJ, Szalai B, Bulusu KC, Guan Y, Yu T, Kang J, Jeon M, Wolfinger R, Nguyen T, Zaslavskiy M, Jang IS, Ghazoui Z, ... ... Garnett MJ, et al. Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen. Nature Communications. 10: 2674. PMID 31209238 DOI: 10.1038/S41467-019-09799-2 |
0.486 |
|
| 2019 |
Picco G, Chen ED, Alonso LG, Behan FM, Gonçalves E, Bignell G, Matchan A, Fu B, Banerjee R, Anderson E, Butler A, Benes CH, McDermott U, Dow D, Iorio F, ... ... Garnett MJ, et al. Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening. Nature Communications. 10: 2198. PMID 31097696 DOI: 10.1038/S41467-019-09940-1 |
0.403 |
|
| 2019 |
Behan FM, Iorio F, Picco G, Gonçalves E, Beaver CM, Migliardi G, Santos R, Rao Y, Sassi F, Pinnelli M, Ansari R, Harper S, Jackson DA, McRae R, Pooley R, ... ... Garnett MJ, et al. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature. PMID 30971826 DOI: 10.1038/S41586-019-1103-9 |
0.478 |
|
| 2019 |
Francies HE, Barthorpe A, McLaren-Douglas A, Barendt WJ, Garnett MJ. Erratum to: Drug Sensitivity Assays of Human Cancer Organoid Cultures. Methods in Molecular Biology (Clifton, N.J.). 1576: 353. PMID 30006863 DOI: 10.1007/7651_2018_138 |
0.342 |
|
| 2018 |
Rajapakse VN, Luna A, Yamade M, Loman L, Varma S, Sunshine M, Iorio F, Sousa FG, Elloumi F, Aladjem MI, Thomas A, Sander C, Kohn KW, Benes CH, Garnett M, et al. CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines. Iscience. PMID 30553813 DOI: 10.1016/J.Isci.2018.11.029 |
0.374 |
|
| 2018 |
Williams SP, Barthorpe AS, Lightfoot H, Garnett MJ, McDermott U. Corrigendum: High-throughput RNAi screen for essential genes and drug synergistic combinations in colorectal cancer. Scientific Data. 5: 180215. PMID 30299440 DOI: 10.1038/sdata.2018.215 |
0.362 |
|
| 2018 |
van der Meer D, Barthorpe S, Yang W, Lightfoot H, Hall C, Gilbert J, Francies HE, Garnett MJ. Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models. Nucleic Acids Research. PMID 30260411 DOI: 10.1093/Nar/Gky872 |
0.314 |
|
| 2018 |
Menden MP, Casale FP, Stephan J, Bignell GR, Iorio F, McDermott U, Garnett MJ, Saez-Rodriguez J, Stegle O. The germline genetic component of drug sensitivity in cancer cell lines. Nature Communications. 9: 3385. PMID 30139972 DOI: 10.1038/S41467-018-05811-3 |
0.418 |
|
| 2018 |
Buczacki SJA, Popova S, Biggs E, Koukorava C, Buzzelli J, Vermeulen L, Hazelwood L, Francies H, Garnett MJ, Winton DJ. Itraconazole targets cell cycle heterogeneity in colorectal cancer. The Journal of Experimental Medicine. 215: 1891-1912. PMID 29853607 DOI: 10.1084/jem.20171385 |
0.352 |
|
| 2018 |
Stammnitz MR, Coorens THH, Gori KC, Hayes D, Fu B, Wang J, Martin-Herranz DE, Alexandrov LB, Baez-Ortega A, Barthorpe S, Beck A, Giordano F, Knowles GW, Kwon YM, Hall G, ... ... Garnett MJ, et al. The Origins and Vulnerabilities of Two Transmissible Cancers in Tasmanian Devils. Cancer Cell. 33: 607-619.e15. PMID 29634948 DOI: 10.1016/j.ccell.2018.03.013 |
0.392 |
|
| 2018 |
Unbekandt M, Belshaw S, Bower J, Clarke M, Cordes J, Crighton D, Croft DR, Drysdale MJ, Garnett MJ, Gill K, Gray C, Greenhalgh DA, Hall JA, Konczal J, Lilla S, et al. Discovery of potent and selective MRCK inhibitors with therapeutic effect on skin cancer. Cancer Research. PMID 29382705 DOI: 10.1158/0008-5472.CAN-17-2870 |
0.439 |
|
| 2018 |
Kolluri KK, Alifrangis C, Kumar N, Ishii Y, Price S, Michaut M, Williams S, Barthorpe S, Lightfoot H, Busacca S, Sharkey A, Yuan Z, Sage EK, Vallath S, Le Quesne J, ... ... Garnett M, et al. Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells. Elife. 7. PMID 29345617 DOI: 10.7554/eLife.30224 |
0.401 |
|
| 2018 |
Picco G, Garnett MJ. A Road Map for Precision Cancer Medicine Using Personalized Models. Cancer Discovery. 7: 456-458. PMID 28461408 DOI: 10.1158/2159-8290.CD-17-0268 |
0.329 |
|
| 2017 |
Garcia-Alonso LM, Iorio F, Matchan A, Fonseca NA, Jaaks P, Peat G, Pignatelli M, Falcone F, Benes CH, Dunham I, Bignell GR, McDade S, Garnett MJ, Saez-Rodriguez J. Transcription factor activities enhance markers of drug sensitivity in cancer. Cancer Research. PMID 29229604 DOI: 10.1158/0008-5472.Can-17-1679 |
0.429 |
|
| 2017 |
Cokelaer T, Chen E, Iorio F, Menden MP, Lightfoot H, Saez-Rodriguez J, Garnett MJ. GDSCTools for Mining Pharmacogenomic Interactions in Cancer. Bioinformatics (Oxford, England). PMID 29186349 DOI: 10.1093/Bioinformatics/Btx744 |
0.399 |
|
| 2017 |
Williams SP, Barthorpe AS, Lightfoot H, Garnett MJ, McDermott U. High-throughput RNAi screen for essential genes and drug synergistic combinations in colorectal cancer. Scientific Data. 4: 170139. PMID 28972570 DOI: 10.1038/sdata.2017.139 |
0.47 |
|
| 2017 |
Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLB, Van den Heuvel APJ, Lev A, Garnett MJ, McDermott U, Benes CH, Batchelor TT, Chi AS, Elemento O, Allen JE, et al. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. Plos One. 12: e0180541. PMID 28767654 DOI: 10.1371/Journal.Pone.0180541 |
0.375 |
|
| 2017 |
Eduati F, Doldàn-Martelli V, Klinger B, Cokelaer T, Sieber A, Kogera F, Dorel M, Garnett MJ, Blüthgen N, Saez-Rodriguez J. Drug Resistance Mechanisms in Colorectal Cancer Dissected with Cell Type-Specific Dynamic Logic Models. Cancer Research. 77: 3364-3375. PMID 28381545 DOI: 10.1158/0008-5472.Can-17-0078 |
0.469 |
|
| 2017 |
Brammeld J, Petljak M, Martincorena I, Williams SP, Alonso LG, Dalmases A, Bellosillo B, Robles-Espinoza CD, Price S, Barthorpe S, Tarpey P, Alifrangis C, Bignell G, Vidal J, Young J, ... ... Garnett M, et al. Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations. Genome Research. PMID 28179366 DOI: 10.1101/Gr.213546.116 |
0.417 |
|
| 2016 |
Bruna A, Rueda OM, Greenwood W, Batra AS, Callari M, Batra RN, Pogrebniak K, Sandoval J, Cassidy JW, Tufegdzic-Vidakovic A, Sammut SJ, Jones L, Provenzano E, Baird R, Eirew P, ... ... Garnett MJ, et al. A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell. PMID 27641504 DOI: 10.1016/j.cell.2016.08.041 |
0.354 |
|
| 2016 |
Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, Aben N, Gonçalves E, Barthorpe S, Lightfoot H, Cokelaer T, Greninger P, van Dyk E, Chang H, de Silva H, ... ... Garnett MJ, et al. A Landscape of Pharmacogenomic Interactions in Cancer. Cell. PMID 27397505 DOI: 10.1016/J.Cell.2016.06.017 |
0.506 |
|
| 2016 |
Saha SK, Gordan JD, Kleinstiver BP, Vu P, Najem MS, Yeo JC, Shi L, Kato Y, Levin RS, Webber JT, Damon LJ, Egan RK, Greninger P, McDermott U, Garnett MJ, et al. Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. Cancer Discovery. 6: 727-39. PMID 27231123 DOI: 10.1158/2159-8290.Cd-15-1442 |
0.454 |
|
| 2016 |
Lynch JT, McEwen R, Crafter C, McDermott U, Garnett MJ, Barry ST, Davies BR. Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen. Oncotarget. PMID 26989080 DOI: 10.18632/oncotarget.8031 |
0.393 |
|
| 2016 |
Ham J, Costa C, Sano R, Lochmann TL, Sennott EM, Patel NU, Dastur A, Gomez-Caraballo M, Krytska K, Hata AN, Floros KV, Hughes MT, Jakubik CT, Heisey DA, Ferrell JT, ... ... Garnett MJ, et al. Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination. Cancer Cell. 29: 159-72. PMID 26859456 DOI: 10.1016/J.Ccell.2016.01.002 |
0.338 |
|
| 2016 |
Michaut M, Chin SF, Majewski I, Severson TM, Bismeijer T, de Koning L, Peeters JK, Schouten PC, Rueda OM, Bosma AJ, Tarrant F, Fan Y, He B, Xue Z, Mittempergher L, ... ... Garnett MJ, et al. Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. Scientific Reports. 6: 18517. PMID 26729235 DOI: 10.1038/srep18517 |
0.321 |
|
| 2015 |
Mardilovich K, Baugh M, Crighton D, Kowalczyk D, Gabrielsen M, Munro J, Croft DR, Lourenco F, James D, Kalna G, McGarry L, Rath O, Shanks E, Garnett MJ, McDermott U, et al. LIM kinase inhibitors disrupt mitotic microtubule organization and impair tumor cell proliferation. Oncotarget. PMID 26540348 DOI: 10.18632/oncotarget.6288 |
0.497 |
|
| 2015 |
Gill SJ, Travers J, Pshenichnaya I, Kogera FA, Barthorpe S, Mironenko T, Richardson L, Benes CH, Stratton MR, McDermott U, Jackson SP, Garnett MJ. Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma. Plos One. 10: e0140988. PMID 26505995 DOI: 10.1371/journal.pone.0140988 |
0.339 |
|
| 2015 |
Francies HE, Garnett MJ. What role could organoids play in the personalization of cancer treatment? Pharmacogenomics. 16: 1523-6. PMID 26485224 DOI: 10.2217/pgs.15.114 |
0.375 |
|
| 2015 |
Hearn JM, Romero-Canelón I, Munro AF, Fu Y, Pizarro AM, Garnett MJ, McDermott U, Carragher NO, Sadler PJ. Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells. Proceedings of the National Academy of Sciences of the United States of America. PMID 26162681 DOI: 10.1073/Pnas.1500925112 |
0.396 |
|
| 2015 |
van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, van Houdt W, van Gorp J, Taylor-Weiner A, Kester L, McLaren-Douglas A, Blokker J, Jaksani S, Bartfeld S, Volckman R, ... ... Garnett MJ, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 161: 933-45. PMID 25957691 DOI: 10.1016/J.Cell.2015.03.053 |
0.342 |
|
| 2014 |
Garnett MJ, McDermott U. The evolving role of cancer cell line-based screens to define the impact of cancer genomes on drug response. Current Opinion in Genetics & Development. 24: 114-9. PMID 24607840 DOI: 10.1016/j.gde.2013.12.002 |
0.439 |
|
| 2013 |
Menden MP, Iorio F, Garnett M, McDermott U, Benes CH, Ballester PJ, Saez-Rodriguez J. Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties. Plos One. 8: e61318. PMID 23646105 DOI: 10.1371/Journal.Pone.0061318 |
0.406 |
|
| 2013 |
He L, Torres-Lockhart K, Forster N, Ramakrishnan S, Greninger P, Garnett MJ, McDermott U, Rothenberg SM, Benes CH, Ellisen LW. Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma. Cancer Discovery. 3: 324-37. PMID 23274910 DOI: 10.1158/2159-8290.CD-12-0417 |
0.344 |
|
| 2013 |
Hart S, Novotny-Diermayr V, Goh KC, Williams M, Tan YC, Ong LC, Cheong A, Ng BK, Amalini C, Madan B, Nagaraj H, Jayaraman R, Pasha KM, Ethirajulu K, Chng WJ, ... ... Garnett M, et al. VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Molecular Cancer Therapeutics. 12: 151-61. PMID 23270925 DOI: 10.1158/1535-7163.MCT-12-0466 |
0.407 |
|
| 2013 |
Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, Ramaswamy S, Futreal PA, Haber DA, Stratton MR, Benes C, ... ... Garnett MJ, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Research. 41: D955-61. PMID 23180760 DOI: 10.1093/Nar/Gks1111 |
0.468 |
|
| 2012 |
Huang S, Hölzel M, Knijnenburg T, Schlicker A, Roepman P, McDermott U, Garnett M, Grernrum W, Sun C, Prahallad A, Groenendijk FH, Mittempergher L, Nijkamp W, Neefjes J, Salazar R, et al. MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling Cell. 151: 937-950. PMID 23178117 DOI: 10.1016/J.Cell.2012.10.035 |
0.455 |
|
| 2012 |
Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 483: 570-5. PMID 22460902 DOI: 10.1038/Nature11005 |
0.523 |
|
| 2012 |
Garnett MJ, McDermott U. Exploiting genetic complexity in cancer to improve therapeutic strategies. Drug Discovery Today. 17: 188-93. PMID 22342219 DOI: 10.1016/j.drudis.2012.01.025 |
0.424 |
|
| 2002 |
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, et al. Mutations of the BRAF gene in human cancer. Nature. 417: 949-54. PMID 12068308 DOI: 10.1038/Nature00766 |
0.31 |
|
| Show low-probability matches. |